Publications
Featured Publications
Immune features ares associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer (nature communications, 2024)
Beckabir W, Zhou M, Lee JS, Vensko SP, Woodcock MG, Wang HH, Wobker SE, Atassi G, Wilkinson AD, Fowler K, Flick LM, Damrauer JS, Harrison MR, McKinnon KP, Rose TL, Milowsky MI, Serody JS, Kim WY, Vincent BG. Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer. Nat Commun. 2024 May 24;15(1):4448. doi: 10.1038/s41467-024-48480-1. PMID: 38789460; PMCID: PMC11126571.
FGFR inhibition augments anti-PD-1 efficacy in murine FGFR3-mutant bladder cancer by abrogating immune suppression (J Clin Invest, 2024)
Okato A*, Utsumi T*, Ranieri M, Zheng X, Zhou M, Pereira LD, Chen T, Kita Y, Wu D, Hyun H, Lee H, Gdowski AS, Raupp JD, Clark-Garvey S, Manocha U, Chafitz A, Sherman F, Stephens J, Rose TL, Milowsky MI, Wobker SE, Serody JS, Damrauer JS, Wong KK#, Kim WY#. PMID: 38226620; PMCID: PMC10786699. (*equal contribution, #co-corresponding authors)
Entinostat Induces Anti-tumor Immune Responses Through Immune Editing of Tumor Neoantigens. (Journal of Clinical Investigation, 2021)
Molecular subtype-specific immunocompetent models of high-grade urothelial carcinoma reveal differential neoantigen expression and response to immunotherapy. (Cancer Research, 2018)
Claudin-low bladder tumors are immune infiltrated and actively immune suppressed (JCI Insight, 2016)
MYC activation cooperates with Vhl and Ink4a/Arf loss to induce clear cell renal cell carcinoma (Nature Communications, 2017)
Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology (Proceedings of the National Academy of Sciences USA, 2014)
Selected Cover Art
Journal of Clinical Investigation, 2024 Issue
About the Cover: Okato, Utsumi, and colleagues report an FGFR3-driven mouse model of bladder cancer that replicates the luminal papillary molecular subtype. Unexpectedly, FGFR inhibition directly counteracts PD-1 blockade–induced Treg expansion. The cover image is an artistic portrayal of the yin and yang of pro- and antitumor inflammation and their intimate association.
Article: Okato A, Utsumi T, Ranieri M, Zheng X, Zhou M, Pereira LD, Chen T, Kita Y, Wu D, Hyun H, Lee H, Gdowski AS, Raupp JD, Clark-Garvey S, Manocha U, Chafitz A, Sherman F, Stephens J, Rose TL, Milowsky MI, Wobker SE, Serody JS, Damrauer JS, Wong KK, Kim WY. FGFR inhibition augments anti-PD-1 efficacy in murine FGFR3-mutant bladder cancer by abrogating immunosuppression. J Clin Invest. 2024.
Cell Reports Medicine, 2022 Issue
About the Cover: We used a networks-based approach to identify DNA damage repair (DDR) genes not associated with TMB yet predictive of immune checkpoint response. The cover depicts a bipartite network of a subset of TCGA samples (blue pentagons, top) and DDR genes (circular nodes, bottom) colored according to DDR pathway membership. Edges link a sample to a mutated gene. A similar (though magnitudes larger) bipartite network was used to derive each gene’s BiG-BET score.
Article: Weir WH, Mucha PJ, Kim WY. A bipartite graph-based expected networks approach identifies DDR genes not associated with TMB yet predictive of immune checkpoint blockade response. Cell Reports Medicine. 2022
Cancer Research, 2018 Issue
About the Cover: Elucidation of intrinsic molecular subtypes of bladder cancer have greatly augmented our understanding of the underlying biologic heterogeneity of urothelial carcinoma. Broadly, bladder cancer molecular subtypes can be divided into basal-like and luminal-like. Using immunofluorescence, it was found that a cell line tumor, BBN963, highly expressed the Krt14 (keratin 14) basal-like marker, but not the Krt20 (keratin 20) protein associated with luminal-like tumors.
Article: Saito R*, Smith CC*, Utsumi T, Bixby LM, Kardos J, Wobker SE, Stewart KG, Chai S, Manocha U, Byrd KM, Damrauer JS, Williams SE, Vincent BG#, Kim WY#. Molecular subtype-specific immunocompetent models of high-grade urothelial carcinoma reveal differential neoantigen expression and response to immunotherapy. Cancer Research. 2018. PMID: 29784854. PMCID: PMC6157276. (*equal contribution, #co-corresponding authors)
Select Publications
2024
Okato A, Utsumi T, Ranieri M, Zheng X, Zhou M, Pereira LD, Chen T, Kita Y, Wu D, Hyun H, Lee H, Gdowski AS, Raupp JD, Clark-Garvey S, Manocha U, Chafitz A, Sherman F, Stephens J, Rose TL, Milowsky MI, Wobker SE, Serody JS, Damrauer JS, Wong KK, Kim WY. FGFR inhibition augments anti-PD-1 efficacy in murine FGFR3-mutant bladder cancer by abrogating immunosuppression. J Clin Invest. 2024 Jan 16;134(2):e169241. doi: 10.1172/JCI169241. PMID: 38226620; PMCID: PMC10786699.
2023
Beckabir W, Wobker, SE, Damrauer JS, Midkiff B, De la Cruze G, Makarov V, Flick L, Woodcock MG, Grivas P, Bjurlin MA, Harrison MR, Vincent BG, Rose TL, Gupta S, Kim WY, Miolosky MI. Spatial Relationships in the Tumor Microenvironment Demonstrate Association with Pathologic Response to Neoadjuvant Chemoimmunotherapy in Muscle-invasive Bladder Cancer. Eur Urol. 2023 Dec 12:S0302-2838(23)03261-X. doi: 10.1016/j.eururo.2023.11.008. Online ahead of print. PMID: 38092611
2022
Damrauer, J. S., Beckabir, W., Klomp, J., Zhou, M., Plimack, E. R., Galsky, M. D., Grivas, P., Hahn, N. M., O’Donnell, P. H., Iyer, G., Quinn, D. I., Vincent, B. G., Quale, D. Z., Wobker, S. E., Hoadley, K. A., Kim, W. Y., & Milowsky, M. I. (2022). Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer. Nature communications, 13(1), 6658. PMID: 36333289
Mirlekar, B., Wang, Y., Li, S., Zhou, M., Entwistle, S., De Buysscher, T., Morrison, A., Herrera, G., Harris, C., Vincent, B. G., Ting, J. P., Rashid, N., Kim, W. Y., Yeh, J. J., & Pylayeva-Gupta, Y. (2022). Balance between immunoregulatory B cells and plasma cells drives pancreatic tumor immunity. Cell reports. Medicine, 3(9), 100744. PMID: 36099917
Weiss, K. G., Matulewicz, R. S., Moreton, E., Shoenbill, K. A., Milowsky, M. I., Rose, T. L., Kim, W. Y., Goldstein, A. O., & Bjurlin, M. A. (2022). History of the Relationship Between Smoking and Bladder Cancer: A Public Health Perspective. Urology, S0090-4295(22)00705-1. Advance online publication. PMID: 35977631
Gessner KH, Kim WY, Zambrano IA. Genomic Meta-analysis of Clear-cell Renal Cell Carcinoma (ccRCC): Aggregating Tumors to Resolve the Complexity of ccRCC. Eur Urol. 2022Jan 24.
Zhou M, Leung JY, Gessner KH, Hepperla AJ, Simon JM, Davis IJ, Kim WY. PBRM1 inactivation promotes upregulation of human endogenous retroviruses in a HIF-dependent manner. Cancer Immunol Res. 2022 Jan 10. PMID: 35013001.
Weir WH, Mucha PJ, Kim WY. A bipartite graph-based expected networks approach identifies DDR genes not associated with TMB yet predictive of immune checkpoint blockade response. Cell Reports Medicine. 2022 In press.
2021
Clark-Garvey S, Kim WY. RAF1 amplification: an exemplar of MAPK pathway activation in urothelial carcinoma. JCI, 2021 Nov 15;131(22):e154095.
Tate T, Xiang T, Zhou M, Kim WY, Chen X, Kim H, Batourina E. Lin S, Lu C, Wobker SE, Mckiernan JM, Mendelsohn CL. Pparg drives luminal differentiation and luminal tumor formation in the urothelium. Nat Comm. 2021 Oct 25;12(1):6160.
Rose TL, Harrison MR, Deal AM, Ramalingam S, Whang YE, Brower B, Dunn M, Osterman CK, Heiling HM, Bjurlin MA, Smith AB, Nielsen ME, Tan HJ, Wallen E, Woods ME, George D, Zhang T, Drier A,Kim WY, Milowsky MI. Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. J Clin Oncol. 2021 Aug 24:JCO2101003. doi: 10.1200/JCO.21.01003. PMID: 34428076. PMCID: PMC8478388.
Rose TL*, Weir WH*, Mayhew GM, Shibata Y, Eulitt P, Uronis JM, Zhou M, Nielsen M, Smith AB, Woods M, Hayward MC, Salazar AH, Milowsky MI, Wobker SE, McGinty K, Millburn MV, Eisner JR, Kim WY. Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience. Br J Cancer. 2021 Oct;125(9):1251-1260. (*equal contribution). PMID: 34294892. PMCID: PMC8548561
Truong AS*, Zhou M*, Krishnan B, Utsumi T, Manocha U, Stewart KG, Beck W, Rose TL, Milowsky MI, He X, Smith CC, Bixby LM, Perou CM, Wobker SE, Bailey ST, Vincent BG, Kim WY. Entinostat Induces Anti-tumor Immune Responses Through Immune Editing of Tumor Neoantigens. JCI, 2021 Aug 16;131(16):e138560.
Damrauer JS, Roell KR, Smith MA, Sun X, Kirk EL, Hoadley KA, Benefield HC, Iyer G, Solit DB, Milowsky MI, Kim WY, Nielsen ME, Wobker SE, Dalbagni G, Al-Ahmadie HA, Olshan AF, Bochner BH, Furberg H, Troester MA, Pietzak EJ. Identification of a novel inflamed tumor microenvironment signature as a predictive biomarker of bacillus Calmette-Guerin immunotherapy in non-muscle invasive bladder cancer. Clin Cancer Res. 2021 Jun 11:clincanres.0205.2021. doi: 10.1158/1078-0432.CCR-21-0205. Online ahead of print. PMID: 34117034. PMCID: PMC8416390
2020
Kardos J, Rose TL, Manocha U, Wobker SE, Damrauer JS, Bivalaqua TJ, Kates M, Moore KJ, Parker JS,Kim WY. Development and validation of a NanoString BASE47 bladder cancer gene classifier. PLoS One. 2020 Dec 17;15(12):e0243935. PMID: 33332422. PMCID: PMC7745986
2019
Manocha U, Kardos J, Selitsky S, Zhou M, Johnson SM, Breslauer C, Epstein JI, Kim WY, Wobker SE. RNA expression profiling of lymphoepithelioma-like carcinoma of the bladder reveals a basal-like molecular subtype. Am J Pathol. 2019 Oct 11. pii: S0002-9440(19)30755-2. PMID: 31610173. PMCID: PMC6943801.
Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS, Al-Ahmadie H, Choi W, Castro MAA, Fontugne J, Eriksson P, Mo Q, Kardos J, Zlotta A, Hartmann A, Dinney CP, Bellmunt J, Powles T, Malats N, Chan KS, Kim WY, McConkey DJ, Black PC, Dyrskjøt L, Höglund M, Lerner SP, Real FX, Radvanyi F; Bladder Cancer Molecular Taxonomy Group. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol. 2019 Sep 26. pii: S0302-2838(19)30695-5. PMID: 31563503. PMCID: PMC7690647.
Jiang Y, Zhang Y, Leung JY, Fan C, Popov KI, Su S, Qian J, Wang X, Holtzhausen A, Ubil E, Xiang Y, Davis I, Dokholyan NV, Wu G, Perou CM, Kim WY, Earp HS, Liu P. MERTK mediated novel site Akt phosphorylation alleviates SAV1 suppression. Nat Commun. 2019 Apr 3;10(1):1515. PMID: 30944303. PMCID: PMC644750.
2018
Gao Y, Kardos J, Yang Y, Tamir TY, Mutter-Rottmayer E, Weissman B, Major MB, Kim WY, Vaziri C. The Cancer/Testes (CT) Antigen HORMAD1 promotes Homologous Recombinational DNA Repair and Radioresistance in Lung adenocarcinoma cells. Sci Rep. 2018 Oct 17;8(1):15304. PMID: 30333500. PMCID: PMC6192992
Rose TL, Chism DD, Alva AS, Deal AM, Maygarden SJ, Whang YE, Kardos J, Drier A, Basch E, Godley PA, Dunn MW, Kim WY, Milowsky MI. Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy. J Cancer. 2018 Oct;119(7):801-807. PMID: 30293995. PMCID: PMC6189143.
Zhang J, Wu T, Simon J, Takada M, Saito R, Fan C, Liu XD, Jonasch E, Xie L, Chen X, Yao X, Teh BT, Tan P, Zheng X, Li M, Lawrence C, Fan J, Geng J, Liu X, Hu L, Wang J, Liao C, Hong K, Zurlo G, Parker JS, Auman JT, Perou CM, Rathmell WK, Kim WY, Kirschner MW, Kaelin WG Jr, Baldwin AS, Zhang Q. VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Science. 2018 Jul 20;361(6399):290-295. PMID: 30026228. PMCID: PMC6154478.
Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, Hakimi AA, Henske EP, Hsieh JJ, Ho TH, Kanchi RS, Krishnan B, Kwiatkowski DJ, Lui W, Merino MJ, Mills GB, Myers J, Nickerson ML, Reuter VE, Schmidt LS, Shelley CS, Shen H, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Vincent BG, Vocke CD, Wheeler DA, Yang L, Kim WY, Robertson AG; Cancer Genome Atlas Research Network, Spellman PT, Rathmell WK, Linehan WM. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Rep. 2018 Jun 19;23(12):3698. PMID: 29925010. PMCID: In progress.
Saito R*, Smith CC*, Utsumi T, Bixby LM, Kardos J, Wobker SE, Stewart KG, Chai S, Manocha U, Byrd KM, Damrauer JS, Williams SE, Vincent BG#, Kim WY#. Molecular subtype-specific immunocompetent models of high-grade urothelial carcinoma reveal differential neoantigen expression and response to immunotherapy. Cancer Research. 2018. PMID: 29784854. PMCID: PMC6157276. (*equal contribution, #co-corresponding authors)
Patel NM*, Michelini VV*, Snell JM, Balu S, Hoyle AP, Parker JS, Hayward MC, Eberhard DA, Salazar AH, McNeillie P, Xu J, Huettner CS, Koyama T, Utro F, Rhrissorrakrai K, Norel R, Bilal E, Royyuru A, Parida L, Earp HS, Grilley-Olson JE, Hayes DN, Harvey SJ, Sharpless NE#, Kim WY#. Enhancing Next-Generation Sequencing-Guided Cancer Care Through Cognitive Computing. Oncologist. 2018 Feb;23(2):179-185. PMID: 29158372. PMCID: PMC5813753. (*equal contribution, #co-corresponding authors)
2017
Kardos J*, Wobker SE*, Woods M, Nielsen ME, Smith AB, Wallen EM, Pruthi RS, Hayward MC, Grilley-Olson JE, Patel NM, Weck K, Black PC, Parker JS, Milowsky MI, Hayes DN#, Kim WY#. Molecular Characterization of Urachal Adenocarcinoma Reveals Commonalities with Colorectal Cancer Including a Hypermutable Phenotype. JCO Precision Oncology. 2017 July 6. DOI: 10.1200/PO.17.00027 (*equal contribution, #co-corresponding authors)
Bailey ST*, Smith AM*, Kardos J, Wobker SE, Wilson HL, Krishnan B, Saito R, Lee HJ, Zhang J, Eaton SC, Williams LA, Manocha U, Peters DJ, Pan X, Carroll TJ, Felsher DW, Walter V, Zhang Q, Parker JS, Yeh JJ, Moffitt RA, Leung JY#, Kim WY#. MYC activation cooperates with Vhl and Ink4a/Arf loss to induce clear cell renal cell carcinoma. Nature Communications. 2017 Jun 8;8:15770. PMID: 28593993. PMCID: PMC5472759. (*equal contribution, #co-corresponding authors)
Leung JY, Wilson HL, Voltzke KJ, Williams LA, Lee HJ, Wobker SE, Kim WY. Sav1 Loss Induces Senescence and Stat3 Activation Coinciding with Tubulointerstitial Fibrosis. Molecular and Cellular Biology. 2017 May 31;37(12). pii: e00565-16. PMID: 28320873 PMCID: PMC5452723.
Choi W, Ochoa A, McConkey DJ, Aine M, Höglund M, Kim WY, Real FX, Kiltie AE, Milsom I, Dyrskjøt L, Lerner SP. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. Eur Urol. 2017 Mar 29. PMID: 28365159. PMCID: PMC5764190.
Miao L, Liu Q, Lin CM, Luo C, Wang Y, Liu L, Yin W, Kim WY, Huang L. Targeting Tumor-associated Fibroblasts for Therapeutic Delivery in Desmoplastic Tumors. Cancer Res. 2017 Feb 1;77(3):719-731. [Epub ahead of print]. PMID: 27864344. PMCID: PMC5290135.
2016
Rose TL, Deal AM, Krishnan B, Nielsen ME, Smith AB, Kim WY, Milowsky MI. Racial disparities in survival among patients with advanced renal cell carcinoma in the targeted therapy era. Cancer. 2016 Oct;122(19):2988-2995. PMID: 27341404. PMCID: PMC5030137.
Lerner SP, Bajorin DF, Dinney CP, Efstathiou JA, Groshen S, Hahn NM, Hansel D, Kwiatkowski D, O’Donnell M, Rosenberg J, Svatek R, Abrams JS, Al-Ahmadie H, Apolo AB, Bellmunt J, Callahan M, Cha EK, Drake C, Jarow J, Kamat A, Kim W, Knowles M, Mann B, Marchionni L, McConkey D, McShane L, Ramirez N, Sharabi A, Sharpe AH, Solit D, Tangen CM, Amiri AT, Van Allen E, West PJ, Witjes JA, Quale DZ. Summary and Recommendations from the National Cancer Institute’s Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bladder Cancer. 2016 Apr 27; 2(2):165-202. PMID: 27376138. PMCID: PMC4927845.
Krishnan BV, Rose TL, Kardos J, Milowsky MI, Kim WY. Intrinsic genomic differences between African-Americans and Caucasians with clear cell renal cell carcinoma. JAMA Oncology. 2016 Mar 24. doi: 10.1001/jamaoncol.2016.0005. [Epub ahead of print]. PMID: 27010573 PMCID: PMC5035632.
Kardos J*, Chai S*, Mose LE, Selitsky, SR, Krishnan B, Saito R, Iglesia MD, Milowsky MI, Parker JS, Kim WY#, and Vincent BG#. Claudin-low bladder tumors are immune infiltrated and actively immune suppressed. JCI Insight. 2016 Mar 17;1(3):e85902. PMID: 27699256. PMCID: PMC5033914. (*equal contribution, #co-corresponding authors)
The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of papillary renal cell carcinoma. N Engl J Med. 2016 Jan 14;374(2):135-145. [Epub ahead of print]. PMID: 26536169. PMCID: PMC4775252.
Lerner SP, McConkey DJ, Hoadley KA, Chan KS, Kim WY, Radvanyi F, Hoglund M, Real FX. Bladder cancer molecular taxonomy: summary from a consensus meeting. Bladder Cancer. 2016 Jan 2(1):37-47. PMID: 27376123. PMCID: PMC4927916.
2010 – 2015
Rose TL, Deal AM, Basch E, Godley PA, Rathmell WK, Kim WY, Whang YE, Dunn MW, Wang A, Chen RC, Nielsen ME, Pruthi RS, Wallen EM, Woods ME, Smith AB, Milowsky MI. Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settings. Urol Oncol. 2015 Sep;33(9):386.e1-6. [Epub ahead of print]. PMID: 26122712. PMCID: PMC5084688.
Chandler RL*, Damrauer JS*, Raab J, Schisler JC, Wilkerson MD, Didion JP, Starmer J, Serber D, Yee D, Xiong J, Darr D, Pardo-Manuel de Villena F, Kim WY, Magnuson T. Coexistent ARID1A-PIK3CA mutations promote ovarian clear cell tumorigenesis through pro-tumorigenic inflammatory cytokine signaling. Nature Communications, 2015 Jan 27;6:6118. PMID: 25625625. PMCID: PMC4308813.
Bailey ST, Zhou B, Damrauer JS, Krishnan B, Wilson HL, Smith AM, Yeh JJ, Kim WY. mTOR inhibition induces compensatory, therapeutically targetable MEK activation in renal cell carcinoma. PLoS One. 2014 Sep 2;9(9):e104413. PMID: 25180793. PMCID: PMC4152178.
Damrauer JS, Hoadley KA, Chism DD, Fan C, Tiganelli CJ, Wobker SE, Yeh JJ, Milowsky MI, Iyer G, Parker JS, Kim WY. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci USA. 2014 Feb 25;111(8):3110-5. PMID: 24520177 PMCID: PMC4009696. (*Highlighted in Nature Reviews Cancer, Science Translational Medicine, Nature Reviews Clinical Oncology.)
Zhou B*, Damrauer JS*, Hadzic T, Jeong Y, Clark K, Fan C, Murphy L, Lee CY, Troester MA, Miller CR, Jin J, Darr D, Perou CM, Levine R, Diehn M, and Kim WY. Erythropoietin promotes breast tumorigenesis through tumor initiating cell self-renewal. *equal contribution. Journal of Clinical Investigation, 2014, Feb 3;124(2):553-63. PMID: 24435044 PMCID: PMC3904607.
Hanna SC, Krishnan B, Bailey ST, Moschos SJ, Kuan PF, Shimamura T, Osborne LD, Siegel, MB, Duncan, LM, O’Brien T, Superfine, R, Miller CR, Simon MC, Wong KK, and Kim WY. HIF1a and HIF2a independently activate SRC to promote melanoma metastases. Journal of Clinical Investigation. 2013 May 1;123(5):2078-93. PMID: 23563312. PMCID: PMC3635738.
Russell RC, Sufan RI, Zhou B, Heir P, Bunda S, Sybingco S, Roche O, Heathcote SA, Chow VWK, Greer SN, Boba LM, Richmond TD, Hickey MM, Barber DL, Cheresh DA, Simon MC, Irwin MS, Kim WY, Ohh M, Loss of JAK2 regulation via VHL-SOCS1 E3 ubiquitin heterocomplex underlies chuvash polycythemia. Nat Med, 2011 Jun 19;17(7):845-53. PMID: 21685897 PMCID: PMC3221316.
Pruthi RS, Nielsen M, Heathcote S, Wallen EM, Rathmell WK, Godley P, Whang Y, Fielding F, Schultz H, Grigson G, and Kim WY. A phase II study of neoadjuvant erlotinib in patients with muscle-invasve bladder cancer undergoing radical cystectomy: clinical and pathological results. BJU Int. 2010 Aug; 106(3): 349-354. PMID: 20089114
2005 – 2009
Kim WY*,†, Perera S*, Zhou B, Carretero J, Yeh JJ, Heathcote SA, Jackson AL, Nikolinakos P, Ospina B, Naumov G, Brandstetter KA, Weigman VJ, Zaghlul S, Hayes DN, Padera RF, Heymach JV, Kung A Sharpless NE, Kaelin WG, and Wong KK, HIF2a cooperates with RAS to promote lung tumorigenesis in mice. Journal of Clinical Investigation. 2009 Aug; 119(8): 2160-70. PMID: 19662677 PMCID: PMC2719950. (†corresponding author, *equal contribution)
Wang Y, Roche O, Yan MS, Finak G, Evans AJ, Metcalf JL, Hast BE, Hanna SC, Wondergem B, Furge KA, Irwin MS, Kim WY, Teh BT, Grinstein S, Park M, Marsden PA, and Ohh M, Regulation of endocytosis via the oxygen-sensing pathway. Nature Medicine. 2009 Mar;15(3):319-24. PMID: 19252501 PMCID: PMC19252501.
Irvin W, MacDonald G, Smith JK, Kim WY, Dexamethasone-induced posterior reversible encephalopathy syndrome. Journal of Clinical Oncology. 2007 Jun 10;25(17):2484-6. PMID: 17557962
Kim WY, Safran M, Buckley RM, Ebert, BL, Glickman J, Bosenberg M, Regan M, Kaelin WG, Jr. Failure to prolyl hydroxylate hifa phenocopies vhl inactivation in vivo. EMBO Journal. 2006 Oct 4;25(19):4650-62. PMID: 16977322 PMCID: PMC1589988.
Review Articles
Leung JY and Kim WY. Bap1 and pbrm1: determinants of tumor grade and mTOR activation in VHL-deficient mouse models of renal cell carcinoma. Cancer Discov. 2017 Aug;7(8):802-804. PMID: 28765116. PMCID: PMC7549016
Yeh JJ and Kim WY. Targeting tumor hypoxia with hypoxia-activated prodrugs. Journal of Clinical Oncology, 2015 Mar 23. PMID: 25800764. PMCID: in process.
Hayes DN and Kim WY. The Next Steps in NextGeneration Sequencing of Cancer Genomes. Journal of Clinical Investigation, 2015 Feb 2;125(2):462-8. PMID: 25642706. PMCID: PMC4319423.
Leung JY and Kim WY. Stearoyl Co-A Desaturase 1 as a ccRCC Therapeutic Target: Death by Stress. Clinical Cancer Research. 2013 Jun 15;19(12):3111-3. PMID: 23709675 PMCID: PMC3898854.
Kim WY and Sharpless NE. Drug Efficacy Testing in Mice. Curr Top Microbiol Immunol. 2011 Aug 7. PMID: 21823029 PMCID: PMC3732649.
Li M and Kim WY. Two sides to every story: the HIF-dependent and HIF-independent roles of pvhl. J Cell Mol Med. 2011 Feb: 15(2) 187-195. PMID: 21155973 PMCID: PMC3229769.
Kim WY and Sharpless NE, VHL inactivation: a new road to senescence. Cancer Cell. 2008 Apr;13(4):295-7. PMID: 18394552
Kim WY and Sharpless NE. The regulation of ink4/arf in cancer and aging. Cell. 2006 Oct 20;127(2) 265-75. PMID: 17055429
Kim, WY and Kaelin, WG. The role of VHL mutation in human cancer. Journal of Clinical Oncology. 2004 Dec;22(24): 4991-5004. PMID: 15611513
Poems
Kim, WY. Whispers of Spring. Annals of Internal Medicine 1996; 125(3): 252. https://doi.org/10.7326/0003-4819-125-3-199608010-00017